REGN Q1 2025 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.0B-3.7% YoY

Gross Profit

$2.6B84.7% margin

Operating Income

$592M19.5% margin

Net Income

$809M26.7% margin

EPS (Diluted)

$7.27

QoQ Revenue Growth

-20.1%

Cash Flow

Operating Cash Flow

$1.0B

Free Cash Flow

$774M

Stock-Based Comp.

$256M

Balance Sheet

Total Assets

$37.5B

Total Liabilities

$8.2B

Stockholders' Equity

$29.4B

Cash & Equivalents

$3.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.0B	$3.1B	-3.7%
Gross Profit	$2.6B	$2.7B	-5.4%
Operating Income	$592M	$751M	-21.3%
Net Income	$809M	$722M	+12.0%

Revenue Segments

Collaboration Revenue

$1.5B51%

Product

$1.4B47%

Product and Service, Other

$82M3%